Sarilumab Effective for Polymyalgia Rheumatica in Phase 3 Trial

Relapsing patients treated with the biologic had significantly higher sustained remission and reported better quality of life, compared with the control group, in a randomized controlled trial.

Related Keywords

New York ,United States ,Pennsylvania ,Hospital For Special Surgery ,Philadelphia ,Abbvie Abbott ,Sebastiane Sattui ,Robert Spiera ,Glaxosmithkline ,Myositis Center ,Boehringer Ingelheim ,American College Of Rheumatology ,Novartis ,Astrazeneca ,University Of Pittsburgh Medical Center Vasculitis Clinic ,American College ,Special Surgery ,New York City ,Lower Risk ,Flare With ,Pittsburgh Medical Center Vasculitis Clinic ,Medscape Medical News ,Biologic Therapy ,Monoclonal Antibody ,Etuximab ,Ituximab ,Glucocorticosteroids ,Remission ,Polymyalgia Rheumatica ,Rheumatoid Arthritis ,A ,Quality Of Life ,Pol ,Ealth Related Quality Of Life ,Rqol ,Vasculitis ,Patient Safety ,Sleep Disorder ,Steroids ,Coronavirus ,019 Novel Coronavirus ,019 Ncov ,Uhan Coronavirus ,Uman Coronavirus Hku1 ,Uman Coronavirus Oc43 ,Ncov ,